CD27

Chr 12AR

CD27 molecule

Also known as: S152, S152. LPFS2, T14, TNFRSF7, Tp55

CD27 encodes a costimulatory immune-checkpoint receptor on T-cells, NK-cells and B-cells that binds CD70 to mediate antigen-specific T-cell activation and expansion, providing immune surveillance of B-cells. Mutations cause lymphoproliferative syndrome 2, an autosomal recessive primary immunodeficiency characterized by abnormal lymphocyte proliferation and immune dysregulation. The gene shows low constraint to loss-of-function variants (pLI 0.01, LOEUF 0.92), consistent with recessive inheritance where heterozygous carriers are typically unaffected.

Summary from RefSeq, OMIM, UniProt
Research Assistant →

Primary Disease Associations & Inheritance

Lymphoproliferative syndrome 2MIM #615122
AR
12
Active trials
378
Pubs (1 yr)
0
P/LP submissions
P/LP missense
0.92
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryCD27
Population Constraint (gnomAD)
Low constraint (pLI 0.01) — loss-of-function variants are relatively tolerated in the population.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.92LOEUF
pLI 0.010
Z-score 1.76
OE 0.44 (0.230.92)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.13Z-score
OE missense 0.97 (0.851.11)
148 obs / 152.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.44 (0.230.92)
00.351.4
Missense OE0.97 (0.851.11)
00.61.4
Synonymous OE0.96
01.21.6
LoF obs/exp: 5 / 11.4Missense obs/exp: 148 / 152.6Syn Z: 0.25
DN
0.7327th %ile
GOF
0.74top 25%
LOF
0.2288th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

CD27 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation

SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants

RECRUITING
NCT06177106Phase NAUniversity of ArizonaStarted 2023-12-26
Solar Simulated Light
Pancreatic CancerIPMN, PancreaticIndividuals at Risk

Pancreatic Cancer Initial Detection Via Liquid Biopsy

ENROLLING BY INVITATION
NCT06283576Karolinska University HospitalStarted 2024-05-01
Liquid biopsy
Multiple Myeloma in Relapse

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

RECRUITING
NCT06282978Phase PHASE2PETHEMA FoundationStarted 2023-11-23
Elranatamab (PF-06863135)
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

RECRUITING
NCT05071222Phase PHASE1, PHASE2Assistance Publique - Hôpitaux de ParisStarted 2023-07-19
ARTEGENE drug product
HIV InfectionsAlcohol DrinkingAging

Precision Microbiota Interventions for Senoreduction Trial

NOT YET RECRUITING
NCT07462767Phase PHASE1, PHASE2Louisiana State University Health Sciences Center in New OrleansStarted 2026-04-01
Limosilactobacillus reuteriBlueberry extract
RhA - Rheumatoid Arthritis

Adversity and Its Association With the Development and Expression of Rheumatic Diseases

NOT YET RECRUITING
NCT06386380National Institute of Medical Sciences and Nutrition, Salvador ZubiranStarted 2024-06-01
Rheumatic diseases Mistreatment Scale (RDMS)Routine assessment of patient index data 3 (RAPID-3)Health Assessment Questionnaire (HAQ)
Platinum-Resistant Ovarian Carcinoma

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

RECRUITING
NCT05225363Phase PHASE1City of Hope Medical CenterStarted 2022-05-05
Chimeric Antigen Receptor T-cellsCyclophosphamideFludarabine
Glioblastoma

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

ACTIVE NOT RECRUITING
NCT03688178Phase PHASE2Annick Desjardins, MDStarted 2020-08-26
Human CMV pp65-LAMP mRNA-pulsed autologous DCsTemozolomideVarlilumab
Post-Acute COVID-19 Syndrome

A Study of Apabetalone in Subjects With Long -COVID

RECRUITING
NCT06590324Phase PHASE2, PHASE3Resverlogix CorpStarted 2025-04-15
Apabetalone
LymphomaMyelomaSolid Tumors

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

NOT YET RECRUITING
NCT07297160Phase PHASE1Baylor College of MedicineStarted 2026-06
Dose Level -1Dose Level 1 (starting dose level)Dose Level 2
Leukemia, Myeloid, AcuteLeukemia, B-cellLeukemia, T-Cell

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

NOT YET RECRUITING
NCT06345027Phase PHASE1Baylor College of MedicineStarted 2026-02
Treatment Arm A
Breast Cancer Early Stage Breast Cancer (Stage 1-3)Prehabilitation

Multimodal Prehabilitation Program That Combines Physical Exercise, Psychological Intervention and Nutritional Support to Improve the Response to Neoadjuvant Chemoterhapy in Early Breast Cancer Patients

RECRUITING
NCT07107594Phase NAHospital Clinic of BarcelonaStarted 2025-01-14
Multimodal prehabilitation
Clinical Literature
Open Research Assistant →